Medicare Enrolled
Dr. Rama Koya, MD
Medical Oncology · Longview, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Koya from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Koya? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Koya
Dr. Rama Koya is a medical oncology in Longview, TX, with 19 years in practice. Based on federal Medicare data, Dr. Koya performed 57,823 Medicare services across 4,776 unique beneficiaries.
Between the years covered by Open Payments, Dr. Koya received a total of $6,688 from 36 pharmaceutical and/or device companies across 100 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Koya is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 17% volume in TX$ $6,688 industry payments
Medicare Practice Summary
Medicare Utilization ↗57,823
Medicare services
Top 17% in TX for medical oncology
4,776
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,043 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Contrast dye for imaging (iodine-based) | 13,581 | $0 | $3 |
| Iron sucrose injection (Venofer) | 11,000 | $0 | $2 |
| Pembrolizumab injection (Keytruda) | 10,400 | $43 | $137 |
| Iron infusion (Feraheme) | 9,180 | $0 | $5 |
| Blood draw (venipuncture) | 2,339 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,889 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,625 | $10 | $64 |
| Dexamethasone injection (steroid) | 728 | $0 | $1 |
| Office visit, established patient (30-39 min) | 601 | $91 | $368 |
| Office visit, established patient (20-29 min) | 442 | $60 | $250 |
| Ferritin level test (iron stores) | 410 | $13 | $60 |
| Iron level test | 393 | $6 | $27 |
| Iron binding capacity test | 393 | $9 | $35 |
| Complete blood count (CBC), automated | 333 | $6 | $34 |
| Microscopic examination for white blood cells with manual cell count | 322 | $4 | $22 |
| Lactate dehydrogenase (enzyme) level | 268 | $6 | $31 |
| Reticulated (young) platelet measurement | 261 | $35 | $143 |
| Anti-nausea injection (Aloxi/palonosetron) | 240 | $1 | $114 |
| Immunoglobulin level test | 219 | $9 | $56 |
| Folic acid level test | 217 | $14 | $73 |
| Vitamin B-12 level test | 213 | $15 | $76 |
| Administration of chemotherapy into vein, 1 hour or less | 174 | $97 | $707 |
| Injection, carboplatin, 50 mg | 152 | $2 | $300 |
| Ct scan of chest with contrast | 129 | $51 | $821 |
| Basic metabolic blood panel | 128 | $8 | $49 |
| Thyroid stimulating hormone (TSH) test | 118 | $16 | $80 |
| Injection of additional new drug or substance into vein | 110 | $11 | $108 |
| CT scan of abdomen and pelvis with contrast | 109 | $168 | $1,067 |
| Carcinoembryonic antigen (cea) protein level | 105 | $19 | $99 |
| Office visit, established patient, complex (40-54 min) | 98 | $131 | $496 |
| Injection, zoledronic acid, 1 mg | 97 | $6 | $431 |
| Uric acid level test | 95 | $4 | $25 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 93 | $22 | $157 |
| Hospital follow-up visit, moderate complexity | 86 | $61 | $247 |
| Drug injection, under skin or into muscle | 81 | $11 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 74 | $46 | $313 |
| Magnesium level test | 68 | $7 | $29 |
| CT scan of chest, without contrast | 66 | $35 | $686 |
| Ct scan of abdomen and pelvis without contrast | 60 | $75 | $560 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 59 | $90 | $657 |
| Injection of drug or substance into vein | 56 | $28 | $247 |
| Injection, diphenhydramine hcl, up to 50 mg | 53 | $1 | $7 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 52 | $1,099 | $4,802 |
| Administration of chemotherapy into vein, each additional hour | 51 | $21 | $164 |
| Administration of additional new drug or substance into vein, 1 hour or less | 51 | $49 | $344 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 51 | $71 | $70 |
| Beta-2 microglobulin (protein) level | 46 | $16 | $96 |
| Chest X-ray, 2 views | 37 | $13 | $61 |
| New patient office visit (45-59 min) | 37 | $112 | $565 |
| Hospital follow-up visit, low complexity | 37 | $38 | $135 |
| PSA test (prostate cancer screening) | 33 | $18 | $94 |
| Blood creatinine level | 32 | $5 | $31 |
| Urea nitrogen level to assess kidney function, quantitative | 32 | $4 | $24 |
| Drawing of blood for a medical problem | 31 | $61 | $264 |
| New patient office visit, complex (60-74 min) | 30 | $159 | $709 |
| Infusion, normal saline solution , 1000 cc | 29 | $2 | $19 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 26 | $349 | $1,722 |
| Unclassified drugs | 26 | $1 | $8 |
| Initial hospital admission, moderate complexity | 24 | $100 | $470 |
| Initial hospital admission, high complexity | 24 | $133 | $694 |
| Irrigation of implanted venous access drug delivery device | 23 | $19 | $114 |
| Administration of additional new drug or substance into vein using push technique | 22 | $42 | $289 |
| Ct scan of soft tissue of neck with contrast | 21 | $51 | $658 |
| Automated urinalysis | 16 | $2 | $16 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $133 | $523 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $25 | $256 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
16.2% high complexity
64.3% medium
19.4% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,688
Total received (2018-2024)
Avg $955/year across 7 years
Top 42% in TX for medical oncology
36
Companies
100
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,923 (58.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,173 (17.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$959 (14.3%)
Other
Charitable contributions, space rental, and other categories
$633 (9.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,844
2023$1,113
2022$2,761
2021$12
2020$350
2019$318
2018$292
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$3,317
Novartis Pharmaceuticals Corporation
$403
BeiGene USA, Inc.
$375
Janssen Biotech, Inc.
$351
Athenex Pharmaceutical Division, LLC
$350
NOVARTIS PHARMACEUTICALS CORPORATION
$299
COMSORT, Inc
$250
ABBVIE INC.
$156
GlaxoSmithKline, LLC.
$97
E.R. Squibb & Sons, L.L.C.
$97
Amgen Inc.
$95
Daiichi Sankyo Inc.
$86
Myriad Genetic Laboratories, Inc.
$81
Pharmacyclics LLC, An AbbVie Company
$70
Lilly USA, LLC
$66
SOBI, INC
$66
Aveo Pharmaceuticals, Inc.
$65
Incyte Corporation
$53
Merck Sharp & Dohme LLC
$49
Astellas Pharma US Inc
$40
Bayer Healthcare Pharmaceuticals Inc.
$38
Blueprint Medicines Corporation
$35
Seagen Inc.
$32
Regeneron Healthcare Solutions, Inc.
$28
Mirati Therapeutics, Inc.
$24
Stemline Therapeutics Inc.
$22
JAZZ PHARMACEUTICALS INC.
$20
Sun Pharmaceutical Industries Inc.
$19
GENZYME CORPORATION
$18
CTI BioPharma Corp.
$17
PUMA BIOTECHNOLOGY, INC.
$14
Seattle Genetics, Inc.
$12
Acrotech Biopharma LLC
$12
Gilead Sciences, Inc.
$12
PFIZER INC.
$12
Janssen Pharmaceuticals, Inc
$8
Top 3 companies account for 61.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BELEODAQ · DARZALEX · DOPTELET · Doptelet · EPKINLY · Enhertu · Erleada · FOTIVDA · IMBRUVICA · IMFINZI · IMJUDO · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LUTATHERA · LYNPARZA · MONJUVI · Nubeqa · OJJAARA · OPDIVO · Odomzo · Orserdu · PADCEV · PLUVICTO · PROMACTA · PreciseTumor · SARCLISA · SCEMBLIX · SHINGRIX · Stivarga · TECVAYLI · VERZENIO · VONJO · Vonjo · XALKORI · Xospata · ZEJULA · ZEPZELCA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (59%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Equivalent to $12 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
3.2
County median income
$64,809
Nearest hospital
CHRISTUS GOOD SHEPHERD MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Koya is a mixed practice specialist, with above-average Medicare volume (top 17% in TX), and consulting-driven industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Koya experienced with contrast dye for imaging (iodine-based)?
Based on Medicare claims data, Dr. Koya performed 13,581 contrast dye for imaging (iodine-based) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Koya receive payments from pharmaceutical companies?
Yes. Dr. Koya received a total of $6,688 from 36 companies across 100 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Koya's costs compare to other medical oncologys in Longview?
Dr. Koya's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Koya) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Longview
Browse medical oncologys in Longview ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
BeiGene USA, Inc. Payments to Doctors
See all physicians who received payments from BeiGene USA, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology